Insider · CIK 0001950499
Peter Blume-Jensen
ceopresidentofficerdirector
Files at ACRV (Acrivon Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 21, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -19,905 | $1.32 | $26k | 2,126,440 | Aug 25, 2025 |
| Aug 14, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -59,766 | $1.39 | $83k | 2,146,345 | Aug 18, 2025 |
| Aug 14, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stockindirect: See Footnote | -490 | $1.39 | $681 | 315,196 | Aug 18, 2025 |
| May 21, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -19,904 | $1.15 | $23k | 2,206,111 | May 23, 2025 |
| May 14, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -59,766 | $1.14 | $68k | 2,226,015 | May 16, 2025 |
| May 14, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stockindirect: See Footnote | -491 | $1.14 | $560 | 315,686 | May 16, 2025 |
| Mar 1, 2025 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +390,390 | $0.00 | $0 | 390,390 | Mar 4, 2025 |
| Mar 1, 2025 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnote | +140,540 | $0.00 | $0 | 140,540 | Mar 4, 2025 |
| Feb 21, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -19,904 | $5.54 | $110k | 2,285,781 | Feb 25, 2025 |
| Feb 14, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -37,152 | $5.42 | $201k | 2,305,685 | Feb 19, 2025 |
| Feb 14, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stockindirect: See Footnote | -579 | $5.42 | $3,138 | 316,177 | Feb 19, 2025 |
| Mar 1, 2024 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +225,226 | $0.00 | $0 | 225,226 | Nov 27, 2024 |
| Mar 1, 2024 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnote | +90,090 | $0.00 | $0 | 90,090 | Nov 27, 2024 |
| Nov 21, 2024 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -19,910 | $6.44 | $128k | 2,342,837 | Nov 25, 2024 |
| Nov 14, 2024 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -59,766 | $7.92 | $473k | 2,362,747 | Nov 18, 2024 |
| Nov 14, 2024 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stockindirect: See Footnote | -490 | $7.92 | $3,881 | 316,756 | Nov 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.